Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
Vertex Announces U.S. FDA Approval For TRIKAFTA To Include Additional Non-F508del TRIKAFTA-Responsive Variants
UBS Says 'Underweight the Names With High China Exposure'
BMO Capital Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $520
J.P. Morgan's Top Healthcare Stocks for 2025
CRISPR Therapeutics Analyst Ratings
Needham Reiterates Hold on Vertex Pharmaceuticalsto Hold